ES Home Catalog Guides COAs Calculator
Retatrutide
Home › Products › Pérdida de Grasa & Metabolism › Retatrutide
← Back to catalog Pérdida de Grasa & MetabolismAvailable

Retatrutide

10 mg / vial
Triple agonistPhase IIIFatty liver

Triple agonist acting on GLP-1, GIP, and Glucagon receptors — the most advanced molecule in its class, currently in Phase III clinical trials.

  • Weight: Up to 24% body weight loss in 48 weeks — class record (TRIUMPH Phase II trial)
  • Fatty liver: Eliminated liver fat in +85% of patients. 93% reached clean liver at 48 weeks (Nature Medicine)
  • Cancer: Reduced pancreatic and lung tumors superior to semaglutide. 40% reduction in prostate cancer (2025 studies)
$165 USD
💰 Buy multiple and save: 3+ vials −5% · 5+ −10%
📋 Technical datasheet · Compound specifications
CompoundRetatrutide
Origin🇺🇸 Lyophilized in USA (US-based facilities)
FormLyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formulaAvailable on request
Molecular weightAvailable on request
Purity≥99% by HPLC + mass spectrometry (Janoshik Analytical)
StorageLyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C, up to 28 days
Recommended solventBacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain2–8°C in transit · controlled thermal packaging
UseResearch Use Only (RUO). Not intended for human or veterinary use.

Typical values for this compound category. For batch-specific data, see the corresponding COA at /en/coa/.

🧪 Lab-verified: Janoshik Analytical · HPLC + MS · Purity ≥99%View COA →
This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.
Questions? Write us

Your Order

Your cart is empty